RenalSense is a privately owned medical device company dedicated to real-time renal diagnostics.

The company’s first commercially available product, Clarity RMS, is a critical care monitoring system that has been clinically proven to facilitate early detection of changes in renal function and acute kidney injury (AKI) risk, in addition to treatment monitoring.

Clarity RMS provides continuous, automatic monitoring of urine flow, enabling better patient care and ICU economics.

It also provides additional real-time parameters and expanded diagnostic capabilities to further improve critical care management in the ICU and perioperative setting.The Clarity RMS system has FDA clearance as well as CE certification and is installed in tens of general and cardiovascular operating rooms, ICUs, and transplant and COVID-19 units in leading medical centers in the U.S., Europe, and Israel.

Future sensor-based products will aim to provide additional diagnostic data about renal and other vital organ function beyond the critical care setting.